The Role of Molecular Analysis in the Diagnosis and Surveillance of Pancreatic Cystic Neoplasms
|
|
- Marsha Hampton
- 5 years ago
- Views:
Transcription
1 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. RESEARCH ARTICLE The Role of Molecular Analysis in the Diagnosis and Surveillance of Pancreatic Cystic Neoplasms Megan Winner, Amrita Sethi 2, John M Poneros 2, Stavros N Stavropoulos, Peter Francisco, Charles J Lightdale 2, John D Allendorf, Peter D Stevens 2,, Tamas A Gonda 2 Departments of Surgery, 2 Division of Digestive and Liver Disease, Department of Medicine, Deceased, Columbia University, New York, Department of Medicine, Surgery, Winthrop University Hospital, Mineola, NY, USA ABSTRACT Context Molecular analysis of pancreatic cyst fluid obtained by EUS-FNA may increase diagnostic accuracy. We evaluated the utility of cystfluid molecular analysis, including mutational analysis of K-ras, loss of heterozygosity (LOH) at tumor suppressor loci, and content in the diagnoses and surveillance of pancreatic cysts. Methods We retrospectively reviewed the Columbia University Pancreas Center database for all patients who underwent EUS/FNA for the evaluation of pancreatic cystic lesions followed by surgical resection or surveillance between We compared accuracy of molecular analysis for mucinous etiology and malignant behavior to cyst-fluid CEA and cytology and surgical pathology in resected tumors. We recorded changes in molecular features over serial encounters in tumors under surveillance. Differences across groups were compared using Student s t or the Mann-Whitney U test for continuous variables and the Fisher s exact test for binary variables. Results Among 0 resected cysts with intermediate-risk features, molecular characteristics increased the diagnostic yield of EUS-FNA (n=) but identified mucinous cysts less accurately than cyst fluid CEA (P=0.2 vs. 0.0). The combination of a K-ras mutation and 2 loss of heterozygosity was highly specific (9%) but insensitive for malignant behavior (0%). Initial data on surveillance (n=) suggests that molecular changes occur frequently, and do not correlate with changes in cyst size, morphology, or CEA. Conclusions In intermediate-risk pancreatic cysts, the presence of a K-ras mutation or loss of heterozygosity suggests mucinous etiology. K-ras mutation plus 2 loss of heterozygosity is strongly associated with malignancy, but sensitivity is low; while the presence of these mutations may be helpful, negative findings are uninformative. Molecular changes are observed in the course of cyst surveillance, which may be significant in long-term follow-up. INTRODUCTION Pancreatic cystic tumors comprise a diverse group of pathologies with variable malignant potential. The need to accurately characterize these tumors is driven by the potential to prevent pancreatic cancer balanced with the risk of performing potentially unnecessary pancreatic surgery. Current treatment guidelines primarily depend on imaging features to stratify tumors by malignant potential [-]. For example, the presence of an associated mass or mural nodule, cystic dilation of the main pancreatic duct, and cyst wall thickening have all been associated with a higher risk of malignancy and are contributing indications for surgical resection [-7]. At the other extreme, honeycomb appearance with central Received November 20th, 20 Accepted January 2th, 20 Keywords Mutational Analysis; Pancreatic Neoplasms; Pancreatic Cyst Correspondence Tamas A Gonda Digestive & Liver Disease 0 West 8th Street Mail Code: PH20-08 New York NY 002 United States Phone Fax tg22@columbia.edu calcification or a pancreatitis-associated cyst favor benign diagnoses of serous cystadenoma and pseudocyst, which warrant no further testing. Unfortunately, the majority of cystic lesions are not easy to categorize. Size cut-off alone has been shown in several studies to be a useful but inconclusive marker of malignancy [7-0]. Fluid aspiration for cytologic and biochemical analysis has emerged as a valuable diagnostic adjunct. EUS-guided cyst fluid aspiration has become a routine procedure and is recommended for most pancreatic cysts when imaging is inconclusive []. While most definitive, cytologic analysis is often low yield. Testing cyst fluid for cancer markers such as carcinoembryonic antigen (CEA) can help characterize cyst etiology. In the largest series to date based on surgical pathology, Brugge and colleagues found an elevated cyst-fluid CEA ( 92 ng/ml) to be a moderately sensitive (7%) and specific (8.%) marker for mucinous cystic tumors [2]. However, as appropriate management is closely tied to the identification of mucinous (i.e.,premalignant) tumors, higher greater diagnostic accuracy is desirable. Furthermore, the correlation between CEA levels and malignancy or risk of progression has not been established [2-]. Recent studies suggest that testing cyst fluid for mutations common to pancreatobiliary neoplasms may increase diagnostic accuracy, both in differentiating mucinous JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ]
2 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. from non-mucinous cysts and detecting malignancy [,, -20]. Our goal was to examine the diagnostic utility of interrogating cyst-fluid aspirates for content and molecular changes at 7 genomic sites, including sequencing for an activating K-ras point mutation and loss of heterozygosity (LOH) analysis of microsatellites located at p, p, q, 9p, 0q, 7p, 7q, 2q, and 22q, in characterizing cystic tumors that had been surgically resected. METHODS Patients and Data Collection We queried our single-center clinical database for patients with a cystic tumor of the pancreas diagnosed between 200 and 20. Pancreatic cystic lesions that were not associated with a mass lesion or occurred in the setting of a known malignancy were included. We retrospectively reviewed prospectively collected data for all patients who underwent molecular analysis of pancreatic cyst fluid prior to surgical resection. We excluded patients in whom a mass or solid component (i.e., a mural nodule) was the target of FNA sampling for molecular analysis. Malignancy was defined when histologic confirmation of invasive adenocarcinoma was obtained at the time of surgical resection. The study was approved by the Columbia University Institutional Review Board. Endosonography and Biochemical Fluid Analysis EUS-FNA was performed with a curvilinear echoendoscope (GIF UC0P, Olympus, Center Valley, PA, USA) using standard 2-, 22-, or 9-gauge needles. Serial exams were performed by the same gastroenterologist. Cytologic evaluation of cyst aspirates employed standard criteria for malignancy and cyst fluid CEA was measured according to routine laboratory protocols. Molecular Analysis Cyst fluid obtained by EUS-FNA was tested (Redpath Integrated Pathology, Pittsburgh, PA, USA) for individual mutations, as previously described [9-]. Molecular criteria suggesting mucinous etiology included: () the presence of a K-ras point mutation; (2) the presence of two or more LOH; or () an elevated quantity of in the specimen. Each specimen was also assigned to a Composite Diagnostic Category of "Favor " and "Favor Aggressive" based on both the clinical impression, fluid cytology, CEA and amylase results as well as the molecular cyst fluid analysis and adjunct tests The Aggressive designation was assigned to any cyst that met criteria for mucinous lesion and had a high amplitude (>7%) K-ras mutation followed by allelic loss. STATISTICS Continuous variables were described by mean and standard deviation (normal distribution) or by median plus interquartile-range (non-normal). Differences across groups were compared using Student s t or the Mann- Whitney U test for continuous variables and the Fisher s exact test for binary variables. Correlation between continuous variables was assessed using linear regression models. All tests were two-tailed; in order to minimize overall type I error, only select associations were tested for statistical significance. Statistical analysis was performed using SAS 9.2 Software (SAS Institute, Inc., Cary, NC, USA). RESULTS Validation of Molecular Analysis against Surgical Pathology Six-hundreds and five patients underwent evaluation for pancreatic cysts between 200 and 202, and 200 patients underwent surgical resection. Among these patients 0 had pre-operative EUS/FNA with cyst fluid molecular analysis. Patient characteristics and cyst features of included cases are shown in Table. Surgical pathology revealed three serous cystadenomas, one vascular malformation, and three neuroendocrine tumors with benign features, all considered benign, non-mucinous tumors. Seven mucinous cystadenomas (MCN) and intraductal papillary mucinous neoplasms (IPMN) with either low-grade (n=7) or borderline dysplasia (n=9) were considered benign, mucinous tumors. Malignant mucinous cysts included two ductal adenocarcinomas and six IPMN with carcinoma in situ (n=) or invasive carcinoma (n=). Malignant nonmucinous cysts included one cholangiocarcinoma and one neuroendocrine tumor with malignant features. The final pathologic designation was based on the surgical pathology report. The cystic lesions aspirated were the only site of biopsy in all of these patients, therefore they are likely not associated cystic degeneration of a primary tumor. Table 2 shows the biochemical and molecular features of 0 cysts and the performance of different criteria in diagnosing mucinous etiology. Cyst fluid was adequate for CEA analysis in 29 cases (72.% overall) and in 2/ (7.7%) mucinous cysts. The sensitivity and specificity in our cohort for determination of mucinous etiology based on CEA 92ng/mL was 78.% and 80.0%. All samples were sufficient for K-ras genotyping but two could not be assessed for loss of heterozygosity (LOH). The presence of a K-ras mutation alone was insensitive (8.%) but highly specific (88.9%) for mucinous etiology. When several molecular indicators were combined into a criterion indicative of mucinous etiology (see methods), the combination of features resulted in an increase sensitivity (79.%) but a decreased specificity (.%) for mucinous pathology. Among nine cysts with a CEA level below 92ng/mL, eight had complete molecular results (including LOH); the molecular criterion for mucinous etiology correctly identified / mucinous and / non-mucinous cysts (accuracy=7%). Among cysts with fluid inadequate for CEA analysis, the molecular criterion correctly identified 7/7 mucinous cysts at the expense of four false positive results. As a result, the addition of molecular to JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ]
3 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. Table : Patient demographic characteristics and cyst radiographic and cytology features of 0 cases used to validate molecular analytic results against surgical pathology. Overall n=0 cysts n=0 Malignant cysts n=0 P Demographic and clinical characteristics Age median (IQR).8(.-7.).(9.-7.2) 8.9( ) 0.8 Female gender 2(0.0%) 8(0.0%) (0.0%).000 White (8.0%) 2(8.%) 9(90.0%).000 Symptomatic a (27.%) 7(2.%) (0.0%) 0.8 Radiographic cyst features Size, cm median (IQR) 9.0( ) 9.0( ) 8.0(.0-2.0) 0.7 Microcystic 7(7.%) (.7%) 2(20.0%).000 Macrocystic (.%) 0(.%) (0.0%) 0.78 Unilocular (7.%) (.%) 2(20.0%) 0.29 Main duct dilatation (0.0%) 2(.7%) 2(20.0%) 0.2 Mass or mural nodule 8(20.0%) (.7%) (0.0%) 0.8 Cytology 0.20 b Malignant Suspicious (80.0%) (.%) 2(20.0%) /atypical 2(0.0%) 8(0.0%) (0.0%) Non-diagnostic 9(2.%) 8(2.7%) (0.0%) Missing or not performed (0.0%) (0.0%) (0.0%) Data shown are number and percent except where indicated. IQR Interquartile range. a Symptomatic presentation was a clinical diagnosis made by the consulting physician at the time of first presentation and was based on the presence of pancreatitis, upper abdominal pain, and obstructive jaundice. b Non-diagnostic tests, as well as missing or not performed, have been excluded from the analysis. Table 2. Associations between cyst fluid biochemical and molecular criteria for mucinous etiology and surgical pathology in 0 pancreatic cysts. Diagnostic test results CEA (n=28) <92 ng/ml 92 ng/ml K-ras point mutation 2 LOH (n=8) Elevated Molecular criterion for mucinous etiology All cases (n=8) Cases missing CEA (n=) CEA 92 ng/ml or molecular criterion Pathologic diagnosis Mucinous (n=) Non-mucinous (n=9) Test performance characteristics Sens Spec PPV NPV Acc 78.% 80.0% 9.7%.% 78.% % 88.9% 9.8%.% 7.% 0.0.0%.7% 7.0% 2.% 9.%.000.% 77.8% 8.% 2.9%.0% %.% 82.% 0.0% 7.% % 0%.% --.% -- 9.%.% 82.% 7.0% 77.% 0.0 Sens: Sensitivity; Spec: Specificity; PPV: positive predictive value; NPV: negative predictive value; Acc: Accuracy, CEA: carcinoembryonic antigen; LOH: loss of heterozygosity P CEA analysis (in which molecular features suggestive of mucinous etiology superseded CEA results) improved the sensitivity for detection of mucinous tumors and importantly increased the diagnostic yield of EUS-FNA (i.e, the number of patients with interpretable results). Table shows the biochemical and molecular features of cysts and the performance of various criteria in diagnosing malignant behavior. A K-ras point mutation was equally likely to be detected in malignant versus mucinous cysts (.%), but malignant cysts were more likely to demonstrate an elevated quantity of (.7% vs. 22.2%, p=0.0) and any loss of heterozygosity (87.% vs. 8.%, p=0.09, see supplementary table ). Detection of both a K-ras point mutation and 2LOH, while poorly sensitive for malignant tumors, was highly specific (9.2%). There was no significant difference in JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ]
4 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. Table. Associations between cyst fluid molecular criteria for malignant behavior and surgical pathology of pancreatic cysts. Diagnostic test results K-ras Elevated LOH (n=) 2 LOH (n=) K-ras and 2 LOH Diagnostic category Favor Favor Aggressive Pathologic diagnosis Malignant (n=9) 7 (n=27) Test performance characteristics Sens Spec PPV NPV Acc.%.% 2.0% 7.0% 2.8%.000.7% 77.8% 0.0% 87.% 7.0% %.%.2% 9.%.9% % 7.9%.% 87.0% 72.2% % 9.2% 80.0% 8.2% 80.% % 8.%.% 88.0% 77.8% 0.02 Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; Acc: accuracy; LOH: loss of heterozygosity Table : Patient demographic characteristics and cyst radiographic, cytologic, and molecular features of case studies used to demonstrate creation of Composite Diagnostic Categories. P Age, gender Cyst features Cyst fluid CEA Cytologic pathology Cyst fluid Case K-ras mutation LOH documents reviewed Composite Diagnostic Category Surgical pathology diagnosis Comment 9 F Asymptomatic 20 mm macrocystic tumor in the body of the pancreas involving the main duct; no mass or mural nodule 29 ng/ml ND Mildly elevated amount of No Yes Cytology report Favor Aggressive IPMC with invasion Elevated amount of incongruous with hypocellularity of cytology specimen F Asymptomatic mm unilocular tumor in the tail of the pancreas, no mass, mural nodule, or duct involvement 27 ng/ml Greatly elevated amount of No No EUS, cytology, and CEA reports Favor Aggressive Mucinous cystic neoplasm Elevated amount of incongruous with hypocellularity of cytology specimen F Symptomatic 22 mm unilocular tumor in the head of the pancreas, no duct involvement but mural nodule seen on EUS Missing Greatly elevated amount of No Yes EUS report Favor Serous cystadenoma Elevated amount of consistent with bloody cytology specimen LOH: loss of heterozygosity, ND: non-diagnostic the accuracy of CEA versus K-ras or LOH in the diagnosis of mucinous cysts or malignancy. A combination of CEA and molecular methods was significantly more sensitive than either CEA or molecular methods combined in the diagnosis of mucinous lesions. Each case was also reviewed based on all available clinical information, fluid characteristics and fluid mutational analysis. A Composite Diagnostic Criteria was created and the cases were classified as "Favor "or "Favor Aggressive". Examples of how this synthesized review may help in the diagnosis are provided in Table. Eleven cases were categorized as "Favor Aggressive "behavior in contrast to cases by molecular criteria alone using the presence of K-ras mutation and >2 LOHs. The sensitivity in this category was.7% and the specificity of the Composite Diagnostic Category was 8.%. Surveillance of Pancreatic Cystic Neoplasms To evaluate the utility of molecular testing in cyst surveillance, we identified patients who had serial EUS-FNA molecular analyses of a pancreatic cyst (7 encounters). Serial examinations were performed a median of 0. months apart, with a range of.0 to.7 months. The median patient age at first encounter was 7. years (range years) and % were female. Baseline median cyst size was 7. mm (IQR mm) and baseline median CEA was 02 ng/ml (IQR 0-78 ng/ml, n=9). Initial cytology was interpreted as benign (n=), atypical (n=7), or non-diagnostic (n=). All patients carried clinical diagnoses of low-grade JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ]
5 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. Table. Evolution of cyst endoscopic, biochemical, and molecular features. ID Age EUS Total time (months) % change cyst size % change CEA K-ras mutation LOH Follow up (months) , mucinous tumors based on presentation and interpretation of radiologic, biochemical, and cytologic testing. Change in Cyst Size and CEA Between serial EUS encounters, the absolute change in cyst size ranged from - mm to + mm. Larger cysts tended to be measured smaller at follow-up (slope -0.29, P=0.008, r 2 =0.). Cyst fluid was adequate for CEA analysis in 27/7 (7.0%) endoscopic encounters, but change in cyst fluid CEA over time could be measured in only nine instances. The percent change in CEA ranged from -% to +,820%. In most cases (8/9) repeat CEA measurement did not change cyst classification based on initial measurements (mucinous vs. non-mucinous). In one instance measured CEA increased from 0 to,889 ng/ml over three endoscopic encounters. Table represents the endoscopic, biochemical, and molecular evolution observed between first and last endoscopic encounters for cysts in individuals. Ten cysts demonstrated newly detected K-ras point mutations or LOH, or an increase in clonality of a previously identified mutation. Three cysts accumulated a pattern of multiple mutations (K-ras and 2 LOH) that was associated with malignancy in the cohort of surgically resected patients (Table ). One patient with accumulation of mutations subsequently underwent total pancreatectomy, which revealed mixed-type IPMN with invasive disease (ID#); the other two remain under surveillance. Cysts with changes in molecular features seemed equally likely to demonstrate size increase (n=), decrease (n=), or no change (n=2). We observed molecular regression (i.e., previously detected mutations were no longer identified) in three cysts, and the molecular profile was stable in three more. Among these six, half demonstrated a change in size >20% between encounters. DISCUSSION We examined the diagnostic accuracy of molecular analysis of pancreatic cyst fluid (i.e., the presence of a K -ras mutation and LOH at tumor-suppressor loci) as compared with surgical pathology in 0 cystic neoplasms; this population tended to be low- or intermediate-risk according to standard criteria for surgical resection [-]. We found that individual molecular alterations were less accurate than cyst fluid CEA in predicting mucinous etiology (P=0.2 vs. P=0.0); however, the combination of K-ras mutation, quantity and LOH was comparable in accuracy and therefore the addition of molecular criteria increased the diagnostic yield of EUS-FNA (i.e., the population with interpretable results, n=). We were not surprised to find that malignant tumors tended to harbor a higher number of mutations; unfortunately, while the combination of a K-ras mutation and 2 LOH was statistically associated with malignancy(p<0.0), this criterion was insensitive (0%). The synthesis of molecular and clinical results into a Composite Diagnostic Category slightly increased sensitivity in detecting malignant behavior (7%). Finally, among cysts under surveillance, many demonstrated changes in the molecular profile over time. The accuracy of molecular features in predicting mucinous etiology and malignant behavior that we observed is similar to results reported by Khalid and colleagues []. In comparing this study with ours, it is important to contrast the examined populations. The aforementioned study included a higher proportion of malignant cysts (% vs. 2% in the present study), and lesions that were symptomatic (9% vs. 29%), of large size (2% cm vs. 2%), and with a solid component (7% vs. 20%). Finally, a cytologic diagnosis of malignancy was obtained in 2% of cases in the aforementioned study as compared to none of the cases described herein. In the current study the detection of a K -ras mutation in cyst fluid aspirates, while specific for mucinous etiology, was insensitive. Rather, the value of molecular analysis was greatest as an adjunct to cyst-fluid CEA measurement, which in our study was the single most accurate criterion for establishing mucinous etiology. Indeed, detection of JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ] 7
6 JOP. J Pancreas (Online) 20 Mar 20; (2):-9. elevated CEA, regardless of the particular cut-off applied by various investigators [2], has endured as the most accurate test in distinguishing mucinous from non-mucinous cysts. Molecular analysis of cyst fluid in combination with CEA levels overcomes the main limitation of the latter assay, namely limited availability in cases of small aspirate volume or highly viscous fluid. We found that the addition of mutational analysis to CEA fluid measurement preserved the high sensitivity and specificity of the latter while increasing the diagnostic yield by almost 0%. In examining the accuracy of molecular analysis in distinguishing malignant from benign cysts, we found that mutations were more numerous in malignant tumors and that the presence of both a K -ras mutation and 2 LOH was significantly associated with malignancy. This objective test was, however, insensitive for malignant behavior; synthesizing molecular analysis with adjunct clinical test results slightly increased the sensitivity for detecting malignant tumors. We therefore propose that molecular analysis in a low- to intermediate-risk pancreatic cyst population may be of particular value in the following situations: () in cytologynegative cysts with elevated CEA( 92 ng/ml) the presence of K -ras mutation followed by LOH is concerning and warrants significant consideration of malignancy; (2) in cytology-negative cysts with low CEA(<92 ng/ml) the presence of K -ras mutation, 2 LOH, or an elevated quantity of should suggest mucinous etiology; and finally, () in otherwise benign-appearing cysts with low CEA(<92 ng/ml) the absence of either K -ras or LOH suggests low probability of mucinous etiology and a low probability of aggressive behavior. When we examined patients under surveillance we found that cyst characterization based on CEA level rarely changed; in addition, we discovered that molecular changes occurred frequently and did not seem to correlate with alterations in size, CEA level, or other features. While our data are not sufficient to draw conclusions at this time, we do envision a role for molecular analysis in the surveillance of low- and intermediate-risk pancreatic cysts. Because cyst fluid CEA measurements are most useful in diagnosis but not prognosis, we recommend against serial CEA measurements once diagnosis (i.e., mucinous vs. nonmucinous) has been established. An exception may be small cysts for which classification by multiple modalities is notoriously difficult. Our study has several limitations, including the retrospective nature and the inability to include the vast majority of cysts sampled during the observational period due to the lack of final pathology. While our patient population was selected for surgical treatment and is therefore inherently biased, we emphasize that our patient population represents an overall lower-risk population than those presented in other similar series. CONCLUSION We have evaluated the utility of molecular cyst fluid analysis in the diagnosis of pancreatic cysts and have found objective molecular features to be useful in the differentiation of mucinous from non-mucinous cysts, especially in cases in which fluid CEA is missing. We have found that the accuracy of molecular features in distinguishing malignant from benign cysts remains suboptimal. Our experience with surveillance of pancreatic cysts is evolving and the role of fluid sampling remains limited. Initial experience indicates that serial resampling of cysts often reveals alterations in the molecular profile. Future prospective studies will answer the question whether these alterations hold clinical meaning and if serial sampling is a useful adjunct to radiographic surveillance. Conflict of Interest Authors declare to have no conflict of interest. References. Tanaka M. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 200;. [PMID: 2728] 2. Khalid A. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. The American journal of gastroenterology. 2007; 02(0): [PMID: 7789]. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International Association of Pancreatology. International consensus guidelines 202 for the management of IPMN and MCN of the pancreas. Pancreatology. 202; 2: 8 97 [PMID:22877]. Khalid A. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut. 200; (2):80-8. [PMID: 229]. Schönleben F. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2008; (2): [PMID: 8708]. Satoh K. K-ras mutation and p protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas. 99; 2(): 2-8. [PMID: 8700] 7. Doi R. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery. 2002; 2(): [PMID: 7982] 8. Sugiyama M. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. British Journal of Surgery. 200; 90(0): [PMID: 29] 9. Choi B. Differential diagnosis of benign and malignant intraductal papillary mucinous tumors of the pancreas: MR cholangiopancreatography and MR angiography. Korean J Radiol. 200; (). [PMID: 0] 0. Matsumoto T. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. Journal of clinical gastroenterology. 200; (): 2-2. [PMID: 29029]. Berland LL. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. Journal of the American College of Radiology. 200; 7(0): [PMID: ] 2. Brugge WR. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (New York, N.Y. 9). 200; 2(): 0-. [PMID: 79]. Lewandrowski KB. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Annals of surgery. 99; 27(): -7. [PMID: 8299] JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ] 8
7 JOP. J Pancreas (Online) 20 Mar 20; (2):-9.. Hammel P. Preoperative cyst fluid analysis is useful for the differential diagnosis of cystic lesions of the pancreas. Gastroenterology (New York, N.Y. 9). 99; 08():20-2. [PMID: 727]. Khalid A. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clinical gastroenterology and hepatology. 200; (0): [PMID: 20]. Schönleben F. PIKCA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbeck's archives of surgery. 2008; 9(): [PMID: 89] 7. Khalid A. Pancreatic cyst fluid analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointestinal endoscopy. 2009; 9(): [PMID: 9289] 8. Khalid A. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut. 200; (2):80-8. [PMID: 229] 9. Hamilton SR. ALA, ed World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System: IARC Press: Lyon Z'Graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernándezdel Castillo C, et al., Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Annals of surgery. 997; 22(): 9-98; discussion [PMID: 977] JOP. Journal of the Pancreas Vol. No. 2 Mar 20. [ISSN ] 9
ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts
ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts Grace H. Elta, MD, FACG 1, Brintha K. Enestvedt, MD, MBA 2, Bryan G. Sauer, MD, MSc, FACG (GRADE Methodologist) 3 and Anne Marie Lennon,
More informationThe role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms
The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms CYSTIC LESIONS AND FLUID COLLECTIONS OF THE PANCREAS Their pathology ranges from pseudocysts and pancreatic necrosis
More informationEvaluation of AGA and Fukuoka Guidelines for EUS and surgical resection of incidental pancreatic cysts
Evaluation of AGA and Fukuoka Guidelines for EUS and surgical resection of incidental pancreatic cysts Authors Alexander Lee 1, Vivek Kadiyala 2,LindaS.Lee 3 Institutions 1 Texas Digestive Disease Consultants,
More informationManagement A Guideline Based Approach to the Incidental Pancreatic Cysts. Common Cystic Pancreatic Neoplasms.
Management 2016 A Guideline Based Approach to the Incidental Pancreatic Cysts ISMRM 2016 Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute
More informationAn Approach to Pancreatic Cysts. Introduction
An Approach to Pancreatic Cysts Nalini M. Guda, MD Aurora St. Luke s Medical Center, Milwaukee Clinical Adjunct Professor of Medicine, University of Wisconsin School of Medicine and Public Health Introduction
More informationPancreatic Cysts. Darius C. Desai, MD FACS St. Luke s University Health Network
Pancreatic Cysts Darius C. Desai, MD FACS St. Luke s University Health Network None Disclosures Incidence Widespread use of cross sectional imaging Seen in over 2% of patients having abdominal imaging
More informationEvaluation and Management of Cystic Lesions of the Pancreas: When to Resect, When to Follow and When to Forget
Evaluation and Management of Cystic Lesions of the Pancreas: When to Resect, When to Follow and When to Forget Randall Brand, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition
More informationOutline. Intraductal Papillary Mucinous Neoplasm (IPMN) Guideline Review 4/6/2017. Case Example Background Classification Histology Guidelines
Intraductal Papillary Mucinous Neoplasm (IPMN) Guideline Review The Nurse Practitioner Association New York State Capital Region Teaching Day Matthew Warndorf MD Case Example Background Classification
More informationMatthew McCollough, M.D. April 9, 2009 University of Louisville
Matthew McCollough, M.D. April 9, 2009 University of Louisville List the differential diagnosis for pancreatic cysts Review the epidemiology Illustrate the types of cysts through case discussions Discuss
More informationChronic pancreatitis mimicking intraductal papillary mucinous neoplasm of the pancreas; Report of tow cases
Jichi Medical University Journal Chronic pancreatitis mimicking intraductal papillary mucinous neoplasm of the pancreas; Report of tow cases Noritoshi Mizuta, Hiroshi Noda, Nao Kakizawa, Nobuyuki Toyama,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PathFinderTG Molecular Testing Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: PathFinderTG Molecular Testing Professional Institutional Original Effective
More informationIntraductal papillary mucinous neoplasm (IPMN) is a distinct
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:815 819 Evaluation of the Guidelines for Management of Pancreatic Branch-Duct Intraductal Papillary Mucinous Neoplasm RAYMOND S. TANG,* BENJAMIN WEINBERG,
More informationCitation American Journal of Surgery, 196(5)
NAOSITE: Nagasaki University's Ac Title Author(s) Multifocal branch-duct pancreatic i neoplasms Tajima, Yoshitsugu; Kuroki, Tamotsu Amane; Adachi, Tomohiko; Mishima, T Kanematsu, Takashi Citation American
More informationMolecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus
Molecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus Policy Number: 2.04.52 Last Review: 8/2018 Origination: 5/2008 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationPersPeCTIves. Controversies in the management of pancreatic ipmn. Masao Tanaka
PersPeCTIves OpiniOn Controversies in the management of pancreatic ipmn Masao Tanaka Abstract Although considerable progress has been made in our understanding of intraductal papillary mucinous neoplasm
More informationCystic pancreatic lesions A proposal for a network approach. Chris Briggs Consultant HPB Surgeon Peninsula HPB Unit Derriford Hospital, Plymouth
Cystic pancreatic lesions A proposal for a network approach Chris Briggs Consultant HPB Surgeon Peninsula HPB Unit Derriford Hospital, Plymouth Aims Brief overview of cystic pancreatic lesions International
More information40th European Congress of Cytology Liverpool, UK, 2-5 th October 2016
40th European Congress of Cytology Liverpool, UK, 2-5 th October 2016 EUS FNA of abdominal organs: An approach to reporting and triage for ancillary testing Date and time: Sunday 2 nd October 2016 15.00-16.30
More informationMolecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus
Molecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus Policy Number: 2.04.52 Last Review: 8/2017 Origination: 5/2008 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationPancreatic Cystic Neoplasms: Guidelines and beyond
Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive Disease Center Professor and Chief, Gastroenterology Vincent & Anna Kong
More informationIntraductal Papillary Mucinous Neoplasms: We Still Have a Way to Go! Francesco M. Serafini, MD, FACS
Intraductal Papillary Mucinous Neoplasms: We Still Have a Way to Go! Francesco M. Serafini, MD, FACS Brooklyn VAMC September 21 st GI Grand Rounds - What is it? - Clinical entity that has emerged from
More informationCase 1. Case 1: EUS Report 5/1/2017. Interesting Cases of Pancreatic Masses
Interesting Cases of Pancreatic Masses Martha Bishop Pitman, MD Professor of Pathology Harvard Medical School Director of Cytopathology Massachusetts General Hospital Boston, MA MASSACHUSETTS GENERAL PHYSICIANS
More informationCystic Pancreatic Lesions: Approach to Diagnosis
Cystic Pancreatic Lesions: Approach to Diagnosis Poster No.: R-0130 Congress: RANZCR-AOCR 2012 Type: Educational Exhibit Authors: A. AGARWAL, R. M. Mendelson; Perth/AU Keywords: Cysts, Biopsy, Endoscopy,
More informationVideo Microscopy Tutorial 19
Video Microscopy Tutorial 19 EUS FNA of Pancreatic Cysts Martha Pitman, MD There are no disclosures necessary. EUS-FNA of Pancreatic Cysts Martha Bishop Pitman, M.D. Massachusetts General Hospital Harvard
More informationResearch Article The Changing Spectrum of Surgically Treated Cystic Neoplasms of the Pancreas
HPB Surgery Volume 2015, Article ID 791704, 7 pages http://dx.doi.org/10.1155/2015/791704 Research Article The Changing Spectrum of Surgically Treated Cystic Neoplasms of the Pancreas Jennifer K. Plichta,
More informationEndoscopic Ultrasonography Clinical Impact. Giancarlo Caletti. Gastroenterologia Università di Bologna. Caletti
Clinical Impact Giancarlo Gastroenterologia Università di Bologna AUSL di Imola,, Castel S. Pietro Terme (BO) 1982 Indications Diagnosis of Submucosal Tumors (SMT) Staging of Neoplasms Evaluation of Pancreato-Biliary
More informationPatient History. A 58 year old man presents with a 16 mm cyst in the pancreatic tail. The cyst is unilocular with a thick wall and no mural nodule.
Case 1 Martha Bishop Pitman, MD Director of Cytopathology Massachusetts General Hospital Associate Professor of Pathology Harvard Medical School Boston, MA Patient History A 58 year old man presents with
More informationSelect problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
More informationTypes of IPMN. Pancreas Cysts: An Incidental Finding or Harbinger of Malignancy. Cysts: Early Neoplasia. Mucinous Cystic Lesions. EUS-guided FNA EUS
Pancreas Cysts: An Incidental Finding or Harbinger of Malignancy EUS-guided FNA William R. Brugge,, MD, FACG Professor of Medicine Harvard Medical School Director, GI Endoscopy Unit Massachusetts General
More informationNonsurgical Management of Asymptomatic Incidental Pancreatic Cysts
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:813 817 Nonsurgical Management of Asymptomatic Incidental Pancreatic Cysts MAOR LAHAV, YAKOV MAOR, BENJAMIN AVIDAN, BEN NOVIS, and SIMON BAR MEIR Department
More informationOriginal article. Introduction!
382 Original article Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: The PIPE Study Authors Won
More informationMolecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus
Molecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationNeoplasias Quisticas del Páncreas
SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard
More informationPancreatic Cystic Lesions 원자력병원
Pancreatic Cystic Lesions 원자력병원 박선 후 Lines of cellular differentiation Ductal Acinar Undetermined Ductal adenocarcinoma Serous/ mucinous tumor Intraductal papillary mucinous neoplasm Acinar cell carcinoma
More informationPancreatico-biliary cytology: a practical approach to diagnosis. Corina Cotoi
Pancreatico-biliary cytology: a practical approach to diagnosis Corina Cotoi Pancreatico-biliary lesions Solid: Ductal adenocarcinoma Cholangiocarcinoma Acinar cell carcinoma Neuroendocrine tumour / carcinoma
More informationPancreatic Cyst. Introduction. EUS Findings of Pancreatic Cysts. Symposium
Symposium Symposium II - Pancreatobiliary System : Endoscopic Approach for the Early Detection of Pancreatobiliary Malignancy in Ji Kon Ryu Department of Internal Medicine, Seoul National University College
More informationHepatobiliary and Pancreatic Malignancies
Hepatobiliary and Pancreatic Malignancies Gareth Eeson MD MSc FRCSC Surgical Oncologist and General Surgeon Kelowna General Hospital Interior Health Consultant, Surgical Oncology BC Cancer Agency Centre
More informationPatient with incidental pancreatic cyst
Clinical problem Diego Aponte M, MD 1 1 Internal Medicine Gastroenterology Specialist. Gastroenterology Academic Coordinator for Graduate Level. Fundación Sanitas. Bogotá, Colombia.... Received: 07-09-10
More informationRole of Endoscopic Ultrasonography in the Diagnosis and Treatment of Cystic Tumors of the Pancreas
ROUND TABLE Role of Endoscopic Ultrasonography in the Diagnosis and Treatment of Cystic Tumors of the Pancreas Manoop S Bhutani Center for Endoscopic Ultrasound - Center for Endoscopic Research, Training
More informationDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai , China
Gastroenterology Research and Practice Volume 216, Article ID 354685, 8 pages http://dx.doi.org/1.1155/216/354685 Research Article Molecular Analyses of Aspirated Cystic Fluid for the Differential Diagnosis
More informationEndoscopic Ultrasound Guided Trucut Biopsy of the Cyst Wall for Diagnosing Cystic Pancreatic Tumors
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:974 979 Endoscopic Ultrasound Guided Trucut Biopsy of the Cyst Wall for Diagnosing Cystic Pancreatic Tumors MICHAEL J. LEVY,* THOMAS C. SMYRK, RAGHURAM P.
More informationOriginal Policy Date
MP 2.04.40 PathFinderTG Molecular Testing Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search12:2013 Return to Medical Policy
More informationPathFinderTG Molecular Testing
Medical Policy Manual Genetic Testing, Policy No. 16 PathFinderTG Molecular Testing Next Review: April 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are developed
More informationTable 1. PathFinderTG Tests (4) Test Description Specimen Type(s) PathFinderTG Pancreas
Subject: PathFinderTG Molecular Testing Page: 1 of 15 Last Review Status/Date: September 2015 PathFinderTG Molecular Testing Description The patented PathFinderTG test is a molecular test to be used adjunctively
More informationCystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time Period
Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time Period Sébastien Gaujoux, MD, PhD, Murray F Brennan, MD, FACS, Mithat
More informationWiriyaporn Ridtitid, John M.DeWitt, C. Max Schmidt, Alexandra Roch, Jennifer Schaffter Stuart, Stuart Sherman, Mohammad A.
Management of Branch duct Intraductal Papillary Mucinous Neoplasms: A Large Single Center Study to Assess Predictors of Malignancy and Long Term Outcomes Wiriyaporn Ridtitid, John M.DeWitt, C. Max Schmidt,
More informationAmerican Gastroenterological Association Institute Guidelines for Management of Asymptomatic Neoplastic Pancreatic Cysts
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 American Gastroenterological Association Institute Guidelines for Management of Asymptomatic Neoplastic Pancreatic Cysts Santhi Swaroop Vege, 1 Barry Ziring, 2 Rajeev
More informationORIGINAL ARTICLE. The Impact of Laparoscopy and Laparoscopic Ultrasound on the Management of Pancreatic
ORIGINAL ARTICLE The Impact of Laparoscopy and Laparoscopic Ultrasound on the Management of Pancreatic Cystic Lesions Pinhas P. Schachter, MD; Yona Avni, MD; Gabriela Gvirtz, MD; Ada Rosen, MD; Abraham
More informationStandardized Terminology in Pancreatobiliary Cytology: The Papanicolaou Society Guidelines
Standardized Terminology in Pancreatobiliary Cytology: The Papanicolaou Society Guidelines Barbara Ann Centeno. M.D. Vice-Chair, Clinical Services, Anatomic Pathology Assistant Chief, Pathology Service
More informationCystic lesions of the pancreas
REVIEW ARTICLE Annals of Gastroenterology (2016) 29, 155-161 Cystic lesions of the pancreas Ioannis Karoumpalis a, Dimitrios K. Christodoulou b General Hospital of Athens G. Gennimatas, Athens; University
More informationDifferential Expression of GNAS and KRAS Mutations in Pancreatic Cysts
ORIGINAL ARTICLE Differential Expression of GNAS and KRAS Mutations in Pancreatic Cysts Linda S Lee 1, Leona A Doyle 2, Jeffrey Houghton 3, Sachin Sah 3, Andrew M Bellizzi 4, Anna E Szafranska-Schwarzbach
More informationIntroduction E389. Background and study aims Guidelines for management
Impact of endoscopic ultrasound on diagnosis and management of presumed mucinous neoplasms when done for pancreatic cyst morphology change on non-invasive surveillance imaging Authors Kamraan Madhani 1,
More informationKenneth D. Chi, MD Medical Director GI Lab Advocate Lutheran General Hospital
Kenneth D. Chi, MD Medical Director GI Lab Advocate Lutheran General Hospital Advances in Digestive Health for the Primary Care Physician Symposium May 2, 2015 None Case Presentation Types of Pancreatic
More informationThe Pancreas. Basic Anatomy. Endocrine pancreas. Exocrine pancreas. Pancreas vasculature. Islets of Langerhans. Acinar cells Ductal System
SGNA: Back to Basics Rogelio G. Silva, MD Assistant Clinical Professor of Medicine University of Illinois at Chicago Department of Medicine Division of Gastroenterology Advocate Christ Medical Center GI
More informationDiagnosis and Management of Cystic Pancreatic Lesions
Gastrointestinal Imaging Best Practices/Review Sahani et al. Cystic Pancreatic Lesions Gastrointestinal Imaging Best Practices/Review Dushyant V. Sahani 1 Avinash Kambadakone 1 Michael Macari 2 Noaki Takahashi
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationSuspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes
Suspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes Evan A. Alston, MD 1 ; Sejong Bae, PhD 2 ; and Isam A. Eltoum, MD, MBA 1 BACKGROUND:
More informationMoving beyond Morphology: New Insights into the Characterization and Management of Cystic Pancreatic Lesions 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Patrick C. Freeny,
More informationX-ray Corner. Imaging of The Pancreas. Pantongrag-Brown L
X-ray Corner 125 Imaging of The Pancreas Modern imaging modalities commonly used in pancreas include ultrasound (US), CT, and MRI. Pancreas is a retroperitoneal organ which makes it difficult to visualize
More informationMural nodules are predictors of malignancy in mucusproducing. Histologic and Imaging Features of Mural Nodules in Mucinous Pancreatic Cysts.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:192 198 Histologic and Imaging Features of Mural Nodules in Mucinous Pancreatic Cysts NING ZHONG,*, LIZHI ZHANG, NAOKI TAKAHASHI, VLADISLAV SHALMIYEV,*
More informationPathFinderTG Molecular Testing
Protocol PathFinderTG Molecular Testing (20452) Medical Benefit Effective Date: 10/01/16 Next Review Date: 07/18 Preauthorization No Review Dates: 09/09, 09/10, 07/11, 07/12, 07/13, 07/14, 07/15, 07/16,
More informationPancreatic cystic lesions are being detected with increasing ORIGINAL ARTICLES
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:967 973 ORIGINAL ARTICLES The Role of Pancreatic Cyst Fluid Molecular Analysis in Predicting Cyst Pathology ASIF KHALID,*, KEVIN M. MCGRATH, MALIHA ZAHID,
More information1 Department of Gastroenterology and Pancreatology, Beaujon Hospital, France 3 Department or Radiology, Beaujon Hospital, University Paris 7, Clichy,
Original Article Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas United European Gastroenterology
More informationIntraductal papillary mucinous neoplasm of the bile ducts: a rare form of premalignant lesion of invasive cholangiocarcinoma
Intraductal papillary mucinous neoplasm of the bile ducts: a rare form of premalignant lesion of invasive cholangiocarcinoma Authors: R. Revert Espí, Y. Fernandez Nuñez, I. Carbonell, D. P. Gómez valencia,
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationPathFinderTG Molecular Testing. Description
Subject: PathFinderTG Molecular Testing Page: 1 of 13 Last Review Status/Date: September 2014 PathFinderTG Molecular Testing Description The patented PathFinderTG test is a molecular test to be used adjunctively
More informationEvaluation of the 2015 AGA guidelines on pancreatic cystic neoplasms in a large surgically confirmed multicenter cohort
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Evaluation of the 2015 AGA guidelines on pancreatic cystic neoplasms in a large surgically confirmed multicenter
More informationCYTOLOGY OF EUS- GUIDED FNA OF THE PANCREAS AND THE UPPER GI TRACT
CYTOLOGY OF EUS- GUIDED FNA OF THE PANCREAS AND THE UPPER GI TRACT Barbara A. Centeno, M.D. Vice-Chair, Clinical Services Assistant Chief of Pathology Director of Cytopathology Department of Anatomic Pathology/Moffitt
More informationSurgical management and results for cystic neoplasms of pancreas
Korean J Hepatobiliary Pancreat Surg 2013;17:118-125 Original Article Surgical management and results for cystic neoplasms of pancreas Kyung Won Han 1, Ryun Ha 1, Kun Kuk Kim 1, Jung Nam Lee 1, Yeon Suk
More informationCystic lesions of the pancreas are composed of a broad
2C: Pancreaticobiliary Problems cystic lesions in the pancreas William R. Brugge, MD, FACG Cystic lesions of the pancreas are composed of a broad range of neoplastic cysts and inflammatory pseudocysts.
More informationSurgical outcomes of multifocal branch duct intraductal papillary mucinous neoplasms of pancreas
Korean J Hepatobiliary Pancreat Surg 2014;18:152-158 http://dx.doi.org/10.14701/kjhbps.2014.18.4.152 Original Article Surgical outcomes of multifocal branch duct intraductal papillary mucinous neoplasms
More informationCASE REPORT. Abstract. Introduction. Case Report
CASE REPORT Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas Involving Type 1 Localized Autoimmune Pancreatitis with Normal Serum IgG4 Levels Successfully Diagnosed by Endoscopic Ultrasound-guided
More informationUnusual Pancreatic Neoplasms RTC 2/11/2011
Unusual Pancreatic Neoplasms RTC 2/11/2011 Objectives Intraductal Papillary Mucinous Neoplasm (IPMN) Mucinous Cystic Neoplasm (MCN) Islet Cell Tumors Insulinoma Glucagonoma VIPoma Somatostatinoma Gastrinoma
More informationROSE in EUS guided FNA of Pancreatic Lesions
ROSE in EUS guided FNA of Pancreatic Lesions Guy s Hospital, London, 16 April 2018 Laxmi Batav Imperial College NHS Trust Imperial College NHS Trust Cytology Workload Cervical Cytology 57,500 (decreases
More informationReview Article Epidemiology, Diagnosis, and Management of Cystic Lesions of the Pancreas
Gastroenterology Research and Practice Volume 2012, Article ID 147465, 8 pages doi:10.1155/2012/147465 Review Article Epidemiology, Diagnosis, and Management of Cystic Lesions of the Pancreas Koen de Jong,
More informationORIGINAL ARTICLE. Fate of the Pancreatic Remnant After Resection for an Intraductal Papillary Mucinous Neoplasm
ONLINE FIRST ORIGINAL ARTICLE Fate of the Pancreatic Remnant After Resection for an Intraductal Papillary Mucinous Neoplasm A Longitudinal Level II Cohort Study Toshiyuki Moriya, MD, PhD; L. William Traverso,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationPathFinderTG Molecular Testing
Protocol PathFinderTG Molecular Testing (20452) Medical Benefit Effective Date: 10/01/14 Next Review Date: 07/15 Preauthorization No Review Dates: 09/09, 09/10, 07/11, 07/12, 07/13, 07/14 The following
More informationIntraductal Papillary Mucinous Neoplasms: The Bologna Experience
ORIGINAL ARTICLE INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM Intraductal Papillary Mucinous Neoplasms: The Bologna Experience Riccardo Casadei 1, Carlo Alberto Pacilio 1, Claudio Ricci 1, Giovanni Taffurelli
More informationPancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
More informationPAPER. Experience With 208 Resections for Intraductal Papillary Mucinous Neoplasm of the Pancreas
PAPER Experience With 0 Resections for Intraductal Papillary Mucinous Neoplasm of the Pancreas Thomas Schnelldorfer, MD; Michael G. Sarr, MD; David M. Nagorney, MD; Lizhi Zhang, MD; Thomas C. Smyrk, MD;
More informationFine-Needle Aspiration Biopsy of Solid Pancreatic Masses: Comparison of CT and Endoscopic Sonography Guidance
Comparison of Guidance Techniques for Pancreatic Mass Biopsy Abdominal Imaging Original Research A C D E M N E U T R Y L I A M C A I G O F I N G Sukru Mehmet Erturk 1 Koenraad J. Mortelé 1 Kemal Tuncali
More informationResearch Article Surgery for Cystic Pancreatic Lesions in the Post-Sendai Era: A Single Institution Experience
HPB Surgery Volume 2015, Article ID 847837, 5 pages http://dx.doi.org/10.1155/2015/847837 Research Article Surgery for Cystic Pancreatic Lesions in the Post-Sendai Era: A Single Institution Experience
More informationGiant pancreatic mucinous cystadenoma with malignant transformation
Case Report Brunei Int Med J. 2014; 10 (3): 177-182 Giant pancreatic mucinous cystadenoma with malignant transformation Jerica CHAI 1, Vui Heng CHONG 2, Ian BICKLE 1 1 Department of Radiology and 2 Department
More informationPancreatic Cysts - Part 2
REVIEW Pancreatic Cysts - Part 2 Should We Be Less Cyst Centric? Anne Marie Lennon, MD, PhD and Marcia Irene Canto, MD, MHS Abstract: The management of pancreatic cysts is a common problem faced by physicians
More informationEndoscopic ultrasound-guided through-the-needle microforceps biopsy in the evaluation of pancreatic cystic lesions: a multicenter study
Endoscopic ultrasound-guided through-the-needle microforceps biopsy in the evaluation of pancreatic cystic lesions: a multicenter study Authors Dennis Yang 1, Jason B. Samarasena 2,LaithH.Jamil 3, Kenneth
More informationDr Claire Smith, Consultant Radiologist St James University Hospital Leeds
Dr Claire Smith, Consultant Radiologist St James University Hospital Leeds Imaging in jaundice and 2ww pathway Image protocol Staging Limitations Pancreatic cancer 1.2.4 Refer people using a suspected
More informationCombatting Pancreatic Cancer: Keys to Early Recognition and Diagnosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/combatting-pancreatic-cancer-keys-earlyrecognition-and-diagnosis/7286/
More informationIntraductal Papillary Mucinous Neoplasm of the Pancreas. Masao Tanaka Editor
Intraductal Papillary Mucinous Neoplasm of the Pancreas Masao Tanaka Editor Intraductal Papillary Mucinous Neoplasm of the Pancreas Masao Tanaka Editor Intraductal Papillary Mucinous Neoplasm of the Pancreas
More informationGenetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
More informationOriginal Article INTRODUCTION
Original Article DOI: 10.3348/kjr.2011.12.2.187 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2011;12(2):187-195 Differentiating Pancreatic Ductal Adenocarcinoma from Pancreatic Serous Cystadenoma, Mucinous
More informationAccuracy of CT in predicting malignant potential of cystic pancreatic neoplasms
HPB, 2008; 10: 483490 ORIGINAL ARTICLE Accuracy of CT in predicting malignant potential of cystic pancreatic neoplasms WILLIAM E. FISHER a, SALLY E. HODGES a, VIVEK YAGNIK b, FANNIE E. MORÓN b, MENG-FEN
More informationDiagnostic performance of endoscopic ultrasound-guided fine-needle aspiration in pancreatic lesions
European Review for Medical and Pharmacological Sciences 2018; 22: 1397-1401 Diagnostic performance of endoscopic in pancreatic lesions Q.-M. WU 1, Y.-N. GUO 1, Y.-Q. XU 1 Digestive Department of Beijing
More informationRole of Endoscopic Ultrasound in the Diagnosis of Intraductal Papillary Mucinous Neoplasms: Correlation With Surgical Histopathology
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:489 495 Role of Endoscopic Ultrasound in the Diagnosis of Intraductal Papillary Mucinous Neoplasms: Correlation With Surgical Histopathology SHIREEN A. PAIS,*
More informationENDOSCOPIC ULTRA SOUND GUIDED FNA OF GI TRACT AND PANCREAS
ENDOSCOPIC ULTRA SOUND GUIDED FNA OF GI TRACT AND PANCREAS Prof. Fernando Schmitt Medical Faculty of Porto University, Porto, Portugal IPATIMUP General Secretary of the International Academy of Cytology
More informationIntraductal Papillary Mucinous Neoplasm of Pancreas
Review Article Intraductal Papillary Mucinous Neoplasm of Pancreas Norman Oneil Machado, Hani al Qadhi, Khalifa al Wahibi Department of Surgery, Sultan Qaboos University Hospital, Muscat, Oman Abstract
More informationThe Use of Pancreatoscopy in the Diagnosis of Intraductal Papillary Mucinous Tumor Lesions of the Pancreas
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S53 S57 The Use of Pancreatoscopy in the Diagnosis of Intraductal Papillary Mucinous Tumor Lesions of the Pancreas KENJIRO YASUDA, MUNEHIRO SAKATA, MOOSE
More informationA large mural nodule in branch duct intraductal papillary mucinous adenoma of the pancreas: a case report
Haruki et al. Surgical Case Reports (2015) 1:20 DOI 10.1186/s40792-014-0009-x CASE REPORT Open Access A large mural nodule in branch duct intraductal papillary mucinous adenoma of the pancreas: a case
More informationFluid analysis prior to surgical resection of suspected mucinous pancreatic cysts. A single centre experience
208 Original Article Fluid analysis prior to surgical resection of suspected mucinous pancreatic cysts. A single centre experience Abdullah Al-Rashdan 1, C. Max Schmidt 2, Mohammad Al-Haddad 1, Lee McHenry
More informationDiagnosis and Management of Primary Sclerosing Cholangitis:
Diagnosis and Management of Primary Sclerosing Cholangitis: The Role of the Endoscopist Adam Slivka MD-PhD Associate Chief of the Division Gastroenterology Hepatology and Nutrition University of Pittsburgh
More information